MedImmune Ventures - aVenture Asset Manager Research
Location
Gaithersburg, MD, US
Founded
1987
MedImmune Ventures functioned as the corporate venture capital investment subsidiary of biotechnology and biologics manufacturer MedImmune. The fund invested early-stage equity capital in emerging life sciences enterprises, biopharmaceutical startups, and innovative medical technology companies. Its investment strategy focused on novel therapeutic modalities, molecular diagnostics, and platform technologies addressing severe unmet medical conditions.
In June 2007, global pharmaceutical corporation AstraZeneca acquired MedImmune and its venture investment operations in an all-cash corporate transaction valued at approximately 15.6 billion dollars. Following the acquisition, MedImmune operated as AstraZeneca's dedicated biologics division until the parent company retired the brand and consolidated global research operations.
MedImmune Ventures - Portfolio Snapshot
Portfolio activity breakdown across disclosed investments and stages
